Here's Why You Should Retain McKesson Stock in Your Portfolio for Now

McKesson (MCK) is supported by 5% North American Pharmaceutical revenue growth and a 19% jump in operating profit to $894M in Q1 FY2027, plus a strong Oncology & Multispecialty performance with revenues up 33% to $14.2B and operating profit up 41%. The company expects GLP-1 distribution revenues of $15B in the quarter (up 24% YoY) and fiscal 2027 operating profit growth of 11%–15%. Offsetting factors include ongoing branded drug pricing pressure from WAC decreases and uncertainty from potential 340B and IRA Part D changes, but Zacks consensus EPS estimates for FY2027 rose by 37 cents to $44.65.

Analysis

MCK is still trading like a high-quality compounder rather than a cyclical distributor, and that distinction matters: specialty mix plus workflow lock-in gives it a better path to sustain EPS growth even when reported revenue looks noisy. The key market mechanism is operating leverage in fee-for-service and access solutions — the business can absorb pricing deflation while still expanding profit, which should keep estimate revisions biased upward over the next 1-3 quarters.

The second-order issue is competitive pressure in specialty distribution and provider services. If MCK’s oncology and access stack continues to win share, smaller regional distributors and less integrated service platforms will need to spend more on technology and field support, which can compress returns across the space. That argues for relative outperformance versus lower-moat healthcare services names, but it also means the moat is operational, not narrative: AI alone is not the edge unless it materially lowers labor cost per transaction or speeds prior auth enough to deepen switching costs.

Contrarian view: the market may be underestimating how much of the recent upside is timing-driven and therefore not fully repeatable, so the stock can drift rather than re-rate sharply. The real risk is policy, not execution — if 340B or Part D changes move from discussion to implementation, the Street will likely mark down terminal margins well before the cash flow impact is visible. Near term the tape can stay constructive; 6-18 months out, the multiple is capped unless MCK proves this is a durable mix shift rather than a temporary beat cycle.

Key Decisions for Investors

• Buy MCK on 2-4% pullbacks over the next 2-6 weeks; use it as a defensive compounder, not a chase after estimate-upgrade headlines. Risk/reward is favorable as long as FY27 EPS revisions keep rising and the stock holds its post-earnings support zone.
• Pair trade: long MCK / short CAH for 1-3 months to isolate specialty/oncology operating leverage versus more commoditized distribution exposure. Falsify if CAH shows faster margin expansion or MCK’s estimate revisions stall.
• Do not add short-dated upside calls in MCK; the better expression is equity or a modest call spread only if you expect another guide-up over the next earnings cycle. The current setup looks steady, not explosive.
• Set a policy alert on 340B and Part D rulemaking for the next 3-12 months. If proposals become concrete or reimbursement mechanics change, reduce exposure before the market reprices long-duration margin assumptions.
• Use any sympathy bid in adjacent healthcare names (e.g., WST, GMED, VCYT) cautiously; this article supports a MCK-specific operating-leverage story more than a broad sector rerating.